YCF’s conferences take a broad theme that gives a variety of speakers the opportunity to set out their own knowledge or experience in different ways. All young companies taking equity investment from business angels or institutional investors (venture capital, private equity, corporate VC) need to…
In this session, Michelle will take us through the top ten considerations when you are looking to either embark on marketing for your business for the first time or revisit your marketing approach and drive a marketing plan. We’ll cover the importance of being data-driven,…
ScreenIn3D Ltd (S3D), a UK-based developer of advanced disease-on-a-chip technologies, has secured £225,000 in seed investment. This investment will be used to further advance and commercialise its enabling microfluidic technologies for advanced drug screening and precision oncology. The £225,000 seed investment in ScreenIn3D was led…
Integrated drug formulation and clinical trials company BDD Pharma has secured £2m in funding to aid expansion in response to growing demand for its patented drug delivery technology and clinical trial services. The round was led by existing investors including Archangels and Scottish Enterprise, along…
Edinburgh-headquartered venture capital firm Par Equity is expanding across the border into Yorkshire with two new offices. Par Equity’s Yorkshire operations comprise bases in Leeds and Sheffield. The move will be overseen by the recently appointed regional development manager Giles Moore. Par Equity has invested…
Cytomos has secured £4m to scale up market testing of its technology platform. The investment round was led by existing investors Archangels, with participation from Old College Capital, Scottish Enterprise and new investor British Business Bank. The Edinburgh-based life science company has developed Cytomos Dielectric…
Archangels has bolstered its funding fire power with a £12m co-investment from British Business Investments via its Regional Angels Programme. The deal will provide the Edinburgh-based angel syndicate with additional capital to back early-stage Scottish life sciences and technology companies. Read more